Bioprocessing White Papers

  1. Is Your Biobank Ready For The Challenge Of Biomarker-Based Research?
    8/19/2013

    In this whitepaper we review the key drivers impacting “traditional” biobanking and detail the challenges such biobanks face in delivering new biomarker-based research. To facilitate the discussion of approaches to overcoming these challenges, we introduce the concept of Next Generation Biobanking and define the attributes an “ideal” Next Generation Biobank would need to drive effective biomarker-based research. Finally we demonstrate the benefits of adopting a Next Generation Biobanking approach, with a case study in cancer biomarker discovery. By Mark A Collins Ph.D., BioFortis, Inc.

  2. How To Avoid The Top 5 LIMS Nightmares
    8/8/2013

    Traditional Laboratory Information Management System (LIMS) implementations are notorious for keeping people awake at night. Industry analysts like Strategic Directions and ARC Advisory Group have estimated the failure rate of commercial LIMS solutions to be as high as 60 percent with many of them failing to deliver original customer requirements after lengthy and expensive deployments.

  3. Stop Holding Your Logistics Manager Accountable
    8/6/2013

    As an executive or decision-maker, you should know there’s a good chance that your company is spending too much on small package shipping. By Brandon Staton

  4. Compliance Cloud - A Life Science Platform
    7/12/2013

    The NextDocs Compliance Cloud is a state-of-the-art delivery platform for the NextDocs compliance suite and was built from the ground up for the Life Sciences industry.

  5. Validation Approaches, Tools, And Services
    7/12/2013

    Validation is a documented process that demonstrates that a system was developed, implemented, operated, and maintained in a controlled manner.

  6. 21 CFR Part 11 Challenges And Solutions
    7/12/2013

    Many sponsors are concerned with the risks and costs involved in ensuring that their electronic systems comply with the FDA’s ruling on acceptance of Electronic Records and Electronic Signatures in place of their paper equivalents (21 CFR Part 11).

  7. Often Disguised As Wolves In SaaS Clothing, SaaS Knockoffs Fail To Live Up To Expectations
    7/11/2013

    While many life sciences system vendors espouse the popular promises of Softwareas-a-Service (SaaS) technology, only a rare few can deliver.

  8. Better Characterization of Biomolecules Using Agilent AdvanceBio Reversed-Phase Columns
    7/2/2013

    Reversed-phase (RP) is one of the three key techniques used in biochromatography and is particularly valuable because of its compatibility with LC/MS detection. And small particle improvements, such as those found in Agilent ZORBAX RRHD 300A, 1.8 um columns, make RP an attractive choice for many biopharmaceutical applications.

  9. Effect Of Sterilization On Mechanical Properties Of Silicone Rubbers
    6/18/2013

    Silicone rubber is widely used in the pharmaceutical industry where sterilizability is an essential requirement for all fluid transfer equipment. Pharmaceutical products must be sterilized frequently and repeatedly by high level energy and/or chemical vapor in order to eliminate bacterial surface contamination.

  10. Considerations When Selecting A CRO For Phase I Clinical Studies
    6/17/2013

    Phase I clinical trials are an integral step in the drug development process. Specific factors can influence the timelines and success of these studies. This white paper addresses the critical success factors for Phase I clinical studies and provides guidance on the appropriate capabilities, expertise and experience to evaluate as a sponsor selects a CRO.